Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.

Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's ...

Medical affairs can no longer afford to operate within legacy structures. Enter AI-enabled functional service provider (FSP) models that offer operational relief.

In healthcare, product launches tend to take on a life of their own. The buildup, the planning, and the expectations all revolve around that single moment when a product finally reaches the market.

Funding for life science startups seeking to raise capital has been tight for the past four years. While there was optimism that 2025 may change the tide, we have not yet seen an ease in the flow of ...

Today we're talking life sciences investment trends and risks with David Sans, an investment banker with an academic background in chemical engineering and molecular modeling, and a professional ...

The life sciences industry is on the brink of a significant shift. Over the next few years, a historic patent cliff will reshape Big Pharma's landscape, triggering waves of talent movement between ...

With the recent sign-off from the FDA on protocols for a pivotal Phase 3 trial of IMNN-001 in advanced ovarian cancer, Imunon is poised to bring its IL-12 DNA plasmid vector (encased in a nanoparticle ...

Artificial intelligence is revolutionizing the life sciences industry by driving innovation in various domains, such as drug discovery, clinical trials, and regulatory compliance. While AI offers the ...